AIM To Exploring the clinical value of serum miR-22 and miR-24 expression in the short-term prognosis of elderly patients with chronic heart failure (CHF).
METHODS A total of 107 elderly CHF patients admitted to the Eastern Theater Command General Hospital from September 2020 to September 2022 were collected and divided into the MACE group (n=43) and non MACE group (n=64) based on whether there were major cardiovascular adverse events (MACE) within 6 months of follow-up; The expression levels of serum miR-22 and miR-24 were detected by qRT PCR method; Logistic regression analysis of the influencing factors of MACE in elderly CHF patients; Receiver operating characteristic was used to analyze the value of serum miR-22 and miR-24 in evaluating the short-term prognosis of elderly CHF.
RESULTS The levels of Blood urea nitrogen (BUN) and creatinine (Cr) in the MACE group were higher than those in the non MACE group, and the ratio of early diastolic mitral flow velocity to late diastolic flow velocity (E/A) in the MACE group was lower than that in the non MACE group, with statistically significant differences (all P<0.01); The serum miR-22 level in the MACE group was higher than that in the non MACE group, while the miR-24 level was lower than that in the non MACE group (all P<0.01); MiR-22 is a risk factor for MACE in elderly CHF patients, while miR-24 is a protective factor (all P<0.01); The AUC of the combined diagnosis of serum miR-22 and miR-24 for CHF patients is 0.921, with a sensitivity of 86.05% and a specificity of 89.94%, which is superior to the individual diagnosis of serum miR-22 and miR-24 (Z combined with miR-22=2.783, Z combined with miR-24=2.147).
Conclusion Serum miR-22 is a risk factor for MACE in elderly CHF patients, while miR-24 is a protective factor, which has good clinical application value for evaluating the prognosis of elderly CHF.
DownLoad: